VanEck Biotech ETF (NASDAQ:BBH) Short Interest Up 110.7% in July

VanEck Biotech ETF (NASDAQ:BBH) was the recipient of a significant growth in short interest in July. As of July 31st, there was short interest totaling 21,232 shares, a growth of 110.7% from the July 15th total of 10,079 shares. Currently, 1.1% of the shares of the stock are short sold. Based on an average trading volume of 5,392 shares, the days-to-cover ratio is presently 3.9 days.

Insider Buying and Selling at VanEck Biotech ETF

In other news, major shareholder Sardar Biglari sold 2,749 shares of the business’s stock in a transaction that occurred on Thursday, July 16th. The shares were sold at an average price of $16.70, for a total value of $45,908.30. Following the completion of the sale, the insider directly owned 3,549,961 shares in the company, valued at approximately $59,284,348.70. The trade was a 0.08% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In the last three months, insiders have sold 10,493 shares of company stock valued at $175,335.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Empowered Funds LLC bought a new position in shares of VanEck Biotech ETF during the fourth quarter valued at about $38,000. Allworth Financial LP lifted its stake in shares of VanEck Biotech ETF by 255.0% in the 4th quarter. Allworth Financial LP now owns 426 shares of the company’s stock valued at $81,000 after acquiring an additional 306 shares during the last quarter. Fifth Third Bancorp bought a new stake in shares of VanEck Biotech ETF in the 1st quarter valued at about $127,000. Huntington National Bank purchased a new stake in VanEck Biotech ETF during the 4th quarter valued at about $132,000. Finally, Evelyn Partners Asset Management Ltd boosted its holdings in VanEck Biotech ETF by 16.9% during the 4th quarter. Evelyn Partners Asset Management Ltd now owns 941 shares of the company’s stock valued at $178,000 after acquiring an additional 136 shares during the period. 32.05% of the stock is owned by institutional investors.

VanEck Biotech ETF Price Performance

Shares of BBH stock traded down $1.72 on Friday, hitting $217.92. 3,436 shares of the company’s stock traded hands, compared to its average volume of 5,691. The company’s fifty day simple moving average is $202.89 and its 200 day simple moving average is $194.35. VanEck Biotech ETF has a one year low of $160.91 and a one year high of $221.11.

VanEck Biotech ETF Company Profile

The BIOTECH HOLDING COMPANY DEPOSITARY RECEIPTS or HOLDRS TRUST was formed under the depositary trust agreement, among The Bank of New York, as trustee, Merrill Lynch, Pierce, Fenner & Smith Incorporated, other depositors and the owners of the Biotech HOLDRS. The trust currently holds shares of common stock or American depositary shares issued by a group of companies that were, at the time of the initial offering, generally considered to be involved in various segments of thebiotechnology industry.